TD early Comments - Will post Butt's comments later LOLEvent This morning, WELL released its Q2/F23 results. Conference call: 1:00 pm ET; 1-888-664-6383. Impact: NEUTRAL Q2/F23 revenue in-line while Adjusted EBITDA beats. Q2/F23 revenue was $170.9mm (TD: $169.9mm/consensus: $169.8mm) and Adjusted EBITDA was $27.8mm (TD: $26.8mm/consensus: $26.4mm). Revenue grew 22% y/y and 1% q/q. Organic growth of 15% YTD and we assume ~10% y/y in Q2/F23. The deceleration from 21% in Q1/F23 is due to the expected slowdowns at Circle (distractions from its rapid clinic expansion) and Wisp (re-tooling its offering) and non-recurring Q1/F23 tailwinds (cybersecurity, one-time O'Regan promotion). Canadian Patient Services revenue of $54.2mm (up 24% y/y). U.S. Patient Services revenue of $103.5mm (up 30% y/y). SaaS and Technology Services revenue of $13.3mm (down 22% y/y due to timing of contracts in its cybersecurity business). SaaS and Technology revenue excluding cybersecurity was $11.3mm (up 29% y/y). Adjusted EBITDA margin was 16.3%, up from 15.7% last quarter, due in part to revenue mix. Net bank debt to shareholder Adjusted EBITDA was 2.3x (down from 3.0x last year). OceanMD signed a $38.5mm contract with the B.C. Provincial Health Services Authority to provide an array of digital services, including eReferrals, eConsults, and eOrders. This follows similar agreements OceanMD has signed with Ontario (where OceanMD is the dominant provider) and Nova Scotia and could help make OceanMD the de facto standard across Canada eventually. The multi-year contract (we assume 5-7 years) includes one-time revenue (e.g., training) with SaaS revenue expected to ramp, as adoption rates increase. F2023 revenue is expected to be in the upper half of guidance while its Adjusted EBITDA outlook was reaffirmed: Revenue of $750mm-$760mm (TD: $743.1mm/consensus: $748.5mm). Previously $740mm-$760mm. Implies ~32-34% y/y growth. Adjusted EBITDA growth of >10%, which implies >$115mm in Adjusted EBITDA (TD: $115.7mm/consensus at $115.8mm). The CarePlus/MCI clinical assets acquisitions and the OceanMD B.C. contract has helped drive the increased F2023 revenue guidance and WELL's confidence in achieving its target to reach $1B in revenue in a couple of years.